Skip to content
Biodatica
Start free

GeoVax, Inc.

Stanford, California

Oncologysmall moleculePhase II
Compare Sign in to watch

What changed

Phase II trial registered: Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

3w agoTrial registeredJun 24, 2026Source filing (opens the source filing in a new tab)

Momentum

81no change

Momentum 81 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Sep 3, 2024

    Nasopharyngeal Carcinoma · RECRUITING · sponsor: Stanford University · Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

    ClinicalTrials.gov · NCT06592599 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Jan 25, 2022

    Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Stanford University · Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

    ClinicalTrials.gov · NCT04925544 (opens the source filing in a new tab)

  3. Trial

    PHASE1/PHASE2 registered

    Feb 11, 2019

    Recurrent Head and Neck Cancer · COMPLETED · sponsor: GeoVax, Inc. · Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

    ClinicalTrials.gov · NCT03754933 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources